The U.S. National Institutes of Health has granted Israel’s Pluri (previously Pluristem) $4.2 million to develop its PLX-R18 (see here) as a treatment for Hematopoietic Acute Radiation Syndrome – a deadly disease that can result from nuclear disasters and radiation … Continue reading →

I reported previously (see here) on the PLX-R18 stem cell treatment for radiation sickness from Israel’s Pluristem. Animal trials by the US Department of Defense demonstrated that PLX-R18, administered before and after radiation exposure increased survival rates by 46-70%. https://www.jpost.com/HEALTH-SCIENCE/Pluristem-gets-positive-results-from-radiation-treatment-trials-597271

I reported previously (see here) on the stem cell treatment of Israel’s Pluristem for radiation sickness. Pluristem’s four-year studies show that its placenta-based PLX-R18 cells are effective as a treatment for radiation damage to the gastrointestinal tract and bone marrow. … Continue reading →

Japan’s Fukushima Medical University and Israel’s Pluristem Therapeutics are to develop Pluristem’s PLX-R18 cells to treat acute radiation syndrome (ARS). Radiation continues to spread following the Fukushima nuclear plant disaster. http://www.timesofisrael.com/japan-turns-to-israeli-tech-to-treat-radiation-disease/